Recombinant Human Erythropoietin Augments Neovascularization Responses in a Neonatal Rat Model of Premature Brain Damage by Phosphatidylinositol 3 Kinase/Akt Pathway

BACKGROUND: Recombinant human-erythropoietin (rh-EPO) has therapeutic efficacy for premature infants with brain damage during the active rehabilitation and anti-inflammation. In the present study, we found that the rh-EPO was related to the promotion of neovascularization. Our aim was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Da-Fan, Zhu, Li-Hua, Jiang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381320/
https://www.ncbi.nlm.nih.gov/pubmed/28345550
http://dx.doi.org/10.4103/0366-6999.202744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381320/
https://www.ncbi.nlm.nih.gov/pubmed/28345550
http://dx.doi.org/10.4103/0366-6999.202744

Ejemplares similares